ArticleScientific reports2023
Establishment of a 96-well transwell system using primary human gut organoids to capture multiple quantitative pathway readouts.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- New developments and applications of human organoids.Nature reviews. Molecular cell biology · 2026Review
- High-throughput histopathology for complex in vitro models.Cell reports methods · 2026Article
- Human colon organoid Transwell model for investigating epithelial growth and repair.npj biomedical innovations · 2026Article
- Assessment of Epithelial Barrier Integrity by TEER and FITC-Dextran Permeability Assays.Bio-protocol · 2026Article
- A long-term human adipocyte organoid model reveals aging-associated responses to intermittent hypoxia.American journal of physiology. Cell physiology · 2026Article
- Advanced human organoid-on-chip with physiological cellular complexity reveals bidirectional secretion patterns.iScience · 2026Article
- A comparative study of organoid-derived and cell line-derived intestinal epithelial models.PloS one · 2026Article
- Functional characteristics of a pig 2D intestinal organoid model as anJournal of animal science and technology · 2026Article
- Development of Long-Term Human Adipocyte Organoids Manifesting Aging in Response to Intermittent Hypoxia.bioRxiv : the preprint server for biology · 2025Article
- A scalable long-termbioRxiv : the preprint server for biology · 2025Article
- Emerging advances in intestinal models for in vitro preclinical research.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- Bridging the Gap: Unlocking the Potential of Biofabrication for Applications in In Vitro Testing.Langmuir : the ACS journal of surfaces and colloids · 2025Review
- Matrix-free human 2D organoids recapitulate duodenal barrier and transport properties.BMC biology · 2025Article
- Review
- Detailed survey of aniScience · 2024Article
- Biomimetic Scaffolds-A Novel Approach to Three Dimensional Cell Culture Techniques for Potential Implementation in Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disruptions in the gut epithelial barrier can lead to the development of chronic indications such as inflammatory bowel disease (IBD). Historically, barrier function has been assessed in cancer cell lines, which do not contain all human intestinal cell types, leading to poor translatability. To bridge this gap, we adapted human primary gut organoids grown as monolayers to quantify transcription factor phosphorylation, gene expression, cytokine production, and barrier function. In this work we describe and characterize a novel 96-well human gut organoid-derived monolayer system that enables quantitative assessment of candidate therapeutics. Normal human intestine differentiation patterns and barrier function were characterized and confirmed to recapitulate key aspects of in vivo biology. Next, cellular response to TNF-α (a central driver of IBD) was determined using a diverse cadre of quantitative readouts. We showed that TNF-α pathway antagonists rescued damage caused by TNF-α in a dose-dependent manner, indicating that this system is suitable for quantitative assessment of barrier modulating factors. Taken together, we have established a robust primary cell-based 96-well system capable of interrogating questions around mucosal response. This system is well suited to provide pivotal functional data to support translational target and drug discovery efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.